Most importantly, this radiosensitisation of mutant p53 tumour cells by transient exposure to a glycolytic inhibitor should be therapeutically achievable, requiring a similar approach to that being used for the dosing of patients in the NIMRAD trial (NCT01950689) with nimorazole 90 min prior to irradiation [51]. Here, TP53 is linked to neoplasm.